We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Denali

News List

Denali Announces Fast Track Designation to DNL310 for Hunter Syndrome americanpharmaceuticalreview
March 18, 2021
Denali Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ETV:IDS (DNL310) for the treatment of patients with Hunter syndrome (MPS II).
Biogen and Denali sign Parkinson’s drug deal worth $2bn pharmaceutical-technology
August 10, 2020
Biogen has entered a binding agreement with Denali Therapeutics to jointly develop and commercialise therapeutics for Parkinson’s disease.
Ex-Genentech Employees' Denali Breaks 2017 IPO Records, Raises $250M biospace
December 11, 2017
Denali Therapeutics, launched in May 2015 by three former Genentech researchers, just went public, raising $250 million with shares priced at $18. It is trading under the ticker DNLI.